Functional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-Frequency Hearing Loss in a

Chelsea M Blankenship1,2, Lisa L Hunter1,2, M Patrick Feeney3,4

  • 1Communication Sciences Research Center, Cincinnati Children's Hospital Medical Center, OH.

Insights

Children with cystic fibrosis (CF) experience higher rates of hearing loss and communication difficulties. Early hearing assessments and monitoring are crucial for managing ototoxicity risks associated with CF treatments.

Area of Science:

  • Audiology
  • Otolaryngology
  • Pediatric Medicine

Background:

  • Cystic Fibrosis (CF) is associated with potential ototoxicity from treatments like aminoglycoside antibiotics.
  • Hearing impairment and its impact on communication in pediatric and young adult CF patients require further investigation.

Purpose of the Study:

  • To determine the prevalence of ototoxicity-related hearing loss in pediatric and young adult CF patients.
  • To assess the functional impact of hearing loss on communication in this cohort.

Main Methods:

  • Observational, cross-sectional study comparing 57 CF patients with 61 age- and gender-matched controls.
  • Utilized standard and extended high-frequency audiometry, middle ear measures, speech perception tests, and questionnaires.

Main Results:

  • CF patients showed 3-4 times higher rates of hearing, balance, and tinnitus issues, and poorer speech perception.
  • Hearing loss prevalence was 57% in CF patients vs. 37% in controls, with CF patients 7.6 times more likely to have moderate or greater hearing loss.
  • CF patients had higher rates of conductive/mixed hearing loss, otitis media, and tympanostomy tube surgeries.

Conclusions:

  • Individuals with CF exhibit increased prevalence of various hearing loss types and otologic symptoms.
  • Poorer speech-in-noise performance and higher rates of tinnitus, dizziness, and imbalance are noted in CF patients.
  • Routine hearing assessments and symptom monitoring are recommended for children with CF, especially before and during ototoxic medication treatment.

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
314
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
95
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
552